How Stimulant Medication for ADHD Developed

The range of ADHD medicines available today looks arbitrary until you know how it accumulated. Nothing about it was designed as a system; it is a sediment of discoveries, reformulations and withdrawals laid down over roughly ninety years. This page traces that history, because it explains several things that otherwise puzzle people — including why a stimulant is used for a condition involving overactivity, and why so many preparations of what is chemically the same medicine exist.

An Accidental Discovery

The therapeutic story begins in the 1930s, when an American physician gave a stimulant to children in a residential unit for an unrelated purpose — he was investigating headaches following a medical procedure. The headaches were unaffected. What he observed instead, and reported, was that a number of the children became calmer and their schoolwork improved.

Two things about this are worth noting. The effect was found by accident, in the course of looking for something else. And it was observed decades before there was any diagnostic framework to explain it: the condition we now call ADHD had no settled name, and the vocabulary of the time described restless or "hyperkinetic" children.

The Mid-Century Medicines

Amphetamine and its derivatives were in wide medical use through the mid-twentieth century for a range of purposes, and dextroamphetamine — the more active isomer — was among the preparations that entered use for attention and behaviour difficulties in children.

Methylphenidate arrived in the same era, a chemically distinct stimulant that became the medicine most associated with the condition for the remainder of the century. From the 1960s onward, as the diagnosis itself was formalised and renamed several times, methylphenidate accumulated the largest evidence base of any medicine used in the field.

What Was Withdrawn

The history includes medicines that are no longer used, and they are instructive.

Pemoline was a stimulant prescribed for attention disorders from the mid-1970s. It was attractive because it was chemically distinct from the amphetamines and less tightly controlled. Reports of serious liver injury, including fatal cases, accumulated over the following decades. Warnings were strengthened, then liver monitoring was required, and it was ultimately withdrawn from the U.S. market in the mid-2000s when regulators concluded the risk was not justified given available alternatives.

Pemoline is worth remembering for a reason beyond itself. A great deal of ADHD writing — including much still circulating online — treats "has been in use for decades" as a proxy for safety. Pemoline had been in use for thirty years when it was withdrawn. Long use establishes familiarity, not safety; what establishes safety is surveillance, and surveillance sometimes changes the answer.

The Reformulation Era

From the 1990s onward, the significant developments were less about new molecules than about delivery.

The problem being solved was practical. Short-acting stimulants wear off within hours, which for a school-age child meant a dose during the school day — administered by a school nurse, in front of other children, with all the disclosure and stigma that involves, and with obvious opportunities for doses to be missed or diverted. Extended-release formulations, using various mechanisms to spread delivery across the day, made a single morning dose viable.

A mixed amphetamine salt product was approved in the mid-1990s; an extended-release methylphenidate product followed at the turn of the century; prodrug formulations, inactive until metabolised, arrived subsequently and were designed partly to reduce misuse potential. This is why the modern list of ADHD medicines is long while the number of underlying chemical families remains two.

Non-Stimulants

The first non-stimulant developed specifically for ADHD was approved in the early 2000s. Its significance was partly clinical and partly regulatory: not being a controlled substance, it altered the practical experience of prescribing and refilling. Other non-stimulant options, including medicines originally developed for other purposes, followed. The medication overview covers the current categories.

What the History Suggests

A few things follow from this account that are useful when reading current claims.

The stimulant effect in attention disorders was observed empirically long before any mechanism was understood, and to a considerable extent that is still the position — the medicines are used because trials show effects, not because the underlying biology is settled. Understanding has followed use rather than preceded it.

The range of available preparations reflects accumulated commercial and practical development, not a graded ladder of increasing strength. And the withdrawal of pemoline is a reminder that the register of what is considered acceptably safe is revised as evidence accumulates.

For what is currently prescribed and what is documented about it, see the methylphenidate page and the amphetamine-class page. MedlinePlus collects current federal material on the condition and its treatment.